MOTS-c: endogenous supply and added peptide

The mitochondrial gene

MOTS-c is a 16-amino-acid peptide encoded within MT-RNR1, the mitochondrial 12S ribosomal RNA gene. The review of its biology follows its presence in muscle and circulation, its metabolic actions and its responses to stress. Mitochondria carry their own DNA; this small peptide gives that genetic material a signaling role beyond the usual picture of energy production.

That origin makes the supply question unusually tempting. The body already makes MOTS-c, so an extra supply can sound like replenishment. I distrust the missing premise: the research described here has not established a clinical deficiency that an added amount corrects in people.

Exercise and extra MOTS-c

Exercise induces endogenous MOTS-c in skeletal muscle and circulation. In the same research program, experiments administering MOTS-c improved physical performance in mice, including treadmill running capacity, grip strength and gait in aged animals. Those intervention results concern mice. The exercise-related observations and the administered peptide cannot simply be folded into one human benefit.

“Exercise mimetic” is a large phrase to place on a small molecule. I’d put two questions to that phrase: which cellular responses overlap with exercise, and which outcomes still depend on an animal experiment?

Inside muscle cells

In cell and animal research, MOTS-c alters folate and purine metabolism, raising AICAR and activating AMPK, a protein that helps cells respond to their energy state. That activity is associated with increased glucose uptake and fat oxidation.

Cell experiments under metabolic stress found nuclear translocation and regulation of stress-response genes. A separate study using cell-free assays and several mouse models identified CK2 as a direct molecular target. CK2 activity increased in muscle and decreased in fat tissue. The opposite tissue responses are a useful warning against imagining a uniform metabolic “boost.” These findings concern cells, binding systems and mice; they supply hypotheses for human experiments.

MOTS-c measured in people

In 94 chronic hemodialysis patients followed for a median 26.5 months, circulating MOTS-c was associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, P=0.05). Adding it to a prediction model increased ROC AUC from 0.727 to 0.743. The patients’ own circulating peptide was measured. Nobody received MOTS-c as the intervention.

Turning a blood measurement into a reason to top up the molecule seems a particularly slippery leap to me. An association with risk can help investigate biology or prediction without showing what an added supply would do.

Human safety and approval

There are no completed human efficacy trials of administered MOTS-c in this record, and no validated human half-life, bioavailability or dose-response data. Its human adverse-effect profile therefore remains unestablished. The review also discusses genetic variation and population-dependent responses. A familiar endogenous molecule can still have unfamiliar consequences when supplied from outside.

MOTS-c has no FDA approval. FDA’s page lists it in the nominated-but-withdrawn table, with safety concerns still recorded. A withdrawn nomination authorizes neither human use nor compounding. Research-labelled material remains on sale, while lawful prescription access requires the applicable clinical, state and compounding conditions to be satisfied. MOTS-c is prohibited in elite sport by anti-doping authorities.

The human evidence needed next is an intervention study that can establish exposure, safety and an outcome in a defined population. The comparison page shows how far that leaves MOTS-c from the other two compounds.